Skip to content

The ED50 and ED95 of esketamine for prevention of postoperative hyperalgesia after remifentanil- based anaesthesia in patients undergoing laparoscopic cholecystectomy

Anesthesiology

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066663
Enrollment
Unknown
Registered
2022-12-13
Start date
2022-12-14
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperalgesia

Interventions

ED95 Group:Intravenous esketamine during anesthesia induction
Control Group:Intravenous equivalent volume of normal saline during anesthesia induction
Experimental Group:Intravenous esketamine during anesthesia induction(ED95)

Sponsors

Affiliated Hospital of Nantong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with full ability to communicate undergoing elective laparoscopic cholecystectomy with general anesthesia, no restriction on gender, ASA status I-?, aged 25 to 75 years, BMI 20-29kg/?.

Exclusion criteria

Exclusion criteria: 1. immediate extubation was not planned after surgery 2.patients with severe preexisting cardiopulmonary, or hepatorenal dysfunction 3. allergying to esketamine, etc. 4. took analgesics regularly or had used opioids within 12 h of surgery 5. unable to comprehend visual analog scale (VAS) 6. had a history of alcohol or drug abuse, psychiatric disorder, or obesity (>130% of ideal body weight) 7. had chronic inflammatory disease 8. intraoperative changeover from laparoscopic to open cholecystectomy 9. had a condition, such as severe hypertension, acute cardiovascular disorder, or a psychiatric disorder, for which the use esketamine was contraindicated.

Design outcomes

Primary

MeasureTime frame
VAS Scoring;ED50 by sequential approach;

Secondary

MeasureTime frame
Demographic data;Intraoperative outcomes;Adverse effects;Vital signs;Prognosis of the studied patients;Resuscitation situations;

Countries

China

Contacts

Public ContactZhongLing Xu

Affiliated Hospital of Nantong University

fJhxzL@163.com13815218918

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026